Molecumetics Ltd.

Choongwae Pharma Corporation

Myriad Genetics, Inc.

University of Illinois

New Turf Technologies, Inc.

University of Southern California

Institute for Chemical Genomics

Other

University of Pennsylvania

Michael S Kahn

Masakatsu Eguchi

Sung Hwan Moon

Jae Uk Chung

Kwang Won Jeong

Sung Chan Lee

Cu Nguyen

Hwa-Ok Kim

Cyprian Okwara Ogbu

Marcin Stasiak

Soo Jin Lee

Patrick Douglas Boatman, Jr

Joseph Ferrara

Jae-Uk Chung

Yi Zhao

John E Tulinsky

Michael R McMillan

Yongfeng Wu

Sung-Hwan Moon

Kwang-Won Jeong

Michael K McMillan

Maher N Qabar

Jessymol Mathew

Jia-Ling Teo

Sung-Chan Lee

Mark I Greene

Jan Urban

Katayoon Hojjati-Emami

SeWoong Oh

DaeHoon Kim

Horacio U Saragovi

JongRyul Ha

Michael Mcmillan

Eguchi Masakatsu

Described herein are devices and systems relating to sports training equipment, for example, for baseball. These devices and systems can comprise a mat with markers identifying a plurality of positions on the mat. In some embodiments, the system can comprise removably attachable footpads to identify ideal foot positions for an athletic performance. In some embodiments, the footpads comprise one or more pressure sensors. The system can comprise one or more position sensors on a ball, and one or more position sensors removably attachable to a hand-held sports instrument. In some embodiments, the system can comprise a memory, communicatively coupled to a processor and a camera, with executable instructions to implement a set-up component, a user recognition component, a practice component, and instructional component, and a play component.

Sports training system

Sports training mat

Provided are: methods for treating aging or an age-related condition, symptom or disease; methods for stimulating hair growth, regrowth or pigmentation (or preventing hair loss); methods for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth); methods for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance). The methods comprise administering a sufficient amount of a CBP/catenin (e.g., CBP/&#x3b2;-catenin) antagonist as disclosed, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population. In particular aspects, the CBP/catenin (e.g., CBP/&#x3b2;-catenin) antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein.

CBP/Catenin antagonists for enhancing asymmetric division of somatic stem cells

Provided are: composition and methods for: treating aging or an age-related condition, symptom or disease; stimulating hair growth, regrowth or pigmentation (or preventing hair loss); for increasing adenosine receptor expression in dermal cells (in combination with hair growth); for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrancy). The methods comprise administering a sufficient amount of the disclosed CBP/catenin (e.g., CBP/(&#x3b2;-catenin) antagonist compositions, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population. In particular aspects, the CBP/catenin (e.g., CBP/(&#x3b2;-catenin) antagonist comprises an alkyl and/or fatty acid ester derivative of formula (I) as disclosed herein 

Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells

Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Reverse-turn mimetics and method relating thereto

The invention provides &#x3b1;-helix mimetic structures and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

Alpha-helix mimetics and methods relating to the treatment of fibrosis

The invention provides &#x3b1;-mimetic structures represented by Formula (VI) and a chemical library relating thereto. Additionally, the invention provides methods wherein &#x3b1;-mimetic compounds are used to treat cancer stem cells. 

Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells

Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility as diagnostic and therapeutic agents for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis. In one embodiment, these reverse-term mimetics have a general structure of formula (VI): wherein R, R, R, X, Xand Xare defined as provided herein.

The invention provides &#x3b1;-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, Rand Ras set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis. 

Growing community of inventors

Kirkland, WA, United States of America

Michael S Kahn